ABCL — AbCellera Biologics Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMid CapFalling Star
- $1.40bn
- $615.68m
- $485.42m
- 69
- 25
- 14
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.18 | ||
| Price to Tang. Book | 1.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 27.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.9% | ||
| Return on Equity | -10.62% | ||
| Operating Margin | -414.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8.83 | 11.61 | 233.16 | 375.2 | 485.42 | 38.64 | 60.82 | 172.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +6.76 | +4.43 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AbCellera Biologics Inc. is a technology company that searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. It rebuilds the platform that integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. The Company partners with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
Directors
- Carl L. Hansen CEO (46)
- Veronique Lecault CFD (36)
- Kevin Heyries CFD
- Andrew Booth CFO (47)
- Ester Falconer CTO (46)
- Tryn Stimart CCO (51)
- Neil Aubuchon OTH
- Neil Berkley OTH
- Michael Hayden IND (69)
- Andrew Lo IND
- John Montalbano IND (56)
- Peter Thiel IND (53)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- November 8th, 2012
- Public Since
- December 11th, 2020
- No. of Shareholders
- 71
- No. of Employees
- 495
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 290,170,241
- Address
- 2215 Yukon Street, VANCOUVER, V5Y 0A1
- Web
- https://www.abcellera.com/
- Phone
- +1 6045599005
- Auditors
- KPMG LLP
Upcoming Events for ABCL
Q1 2024 Abcellera Biologics Inc Earnings Release
Similar to ABCL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
Acelyrin
NASDAQ Global Select Market
FAQ
What is the AbCellera Biologics share price?
As of Today at 18:00 UTC, shares in AbCellera Biologics are trading at $4.83. This share price information is delayed by 15 minutes.
How has the AbCellera Biologics share price performed this year?
Shares in AbCellera Biologics last closed at $4.83 and the price had moved by -63.35% over the past 365 days. In terms of relative price strength the AbCellera Biologics share price has underperformed the S&P500 Index by -67.52% over the past year.
What are the analyst and broker recommendations for AbCellera Biologics?
The overall consensus recommendation for AbCellera Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the AbCellera Biologics dividend yield?
AbCellera Biologics does not currently pay a dividend.
Does AbCellera Biologics pay a dividend?
AbCellera Biologics does not currently pay a dividend.
When does AbCellera Biologics next pay dividends?
AbCellera Biologics does not currently pay a dividend.
How do I buy AbCellera Biologics shares?
To buy shares in AbCellera Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AbCellera Biologics?
As of the previous close price of $4.83, shares in AbCellera Biologics had a market capitalisation of $1.40bn.
Where are AbCellera Biologics shares listed?
Here are the trading details for AbCellera Biologics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABCL
What kind of share is AbCellera Biologics?
Based on an overall assessment of its quality, value and momentum AbCellera Biologics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AbCellera Biologics share price forecast for 2023?
The analyst consensus target price for shares in AbCellera Biologics is $22.00. That is 355.49% above the last closing price of $4.83.
Analysts covering AbCellera Biologics currently have a consensus Earnings Per Share (EPS) forecast of -$0.47 for the next financial year.
What is the trend in the AbCellera Biologics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AbCellera Biologics. Over the past six months, its share price has underperformed the S&P500 Index by -33.83%.
As of the last closing price of $4.83, shares in AbCellera Biologics were trading -22.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AbCellera Biologics PE Ratio?
The AbCellera Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AbCellera Biologics?
AbCellera Biologics' management team is headed by:
- Carl L. Hansen - CEO
- Veronique Lecault - CFD
- Kevin Heyries - CFD
- Andrew Booth - CFO
- Ester Falconer - CTO
- Tryn Stimart - CCO
- Neil Aubuchon - OTH
- Neil Berkley - OTH
- Michael Hayden - IND
- Andrew Lo - IND
- John Montalbano - IND
- Peter Thiel - IND